Stock Traders Purchase High Volume of Call Options on Repare Therapeutics (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX) was the recipient of unusually large options trading activity on Monday. Stock traders acquired 13,699 call options on the company. This is an increase of 9,685% compared to the average volume of 140 call options.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC increased its holdings in Repare Therapeutics by 35.6% in the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after buying an additional 168,230 shares in the last quarter. Rangeley Capital LLC purchased a new stake in shares of Repare Therapeutics during the 2nd quarter valued at about $494,000. Affinity Asset Advisors LLC grew its stake in shares of Repare Therapeutics by 100.0% in the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock worth $197,000 after acquiring an additional 100,000 shares during the period. Militia Capital Partners LP bought a new stake in shares of Repare Therapeutics in the second quarter worth approximately $166,000. Finally, Squarepoint Ops LLC bought a new position in Repare Therapeutics during the third quarter valued at approximately $115,000. 85.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on RPTX. Wall Street Zen raised shares of Repare Therapeutics to a “hold” rating in a research report on Saturday. HC Wainwright lowered their target price on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.50.

Repare Therapeutics Stock Up 29.4%

Shares of NASDAQ RPTX traded up $0.49 during midday trading on Monday, hitting $2.14. The stock had a trading volume of 4,546,666 shares, compared to its average volume of 291,599. The business’s 50 day moving average is $1.78 and its 200-day moving average is $1.59. Repare Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.07. The company has a market cap of $91.72 million, a P/E ratio of -1.26 and a beta of 1.06.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.43. The firm had revenue of $11.62 million during the quarter, compared to analysts’ expectations of $7.50 million. As a group, analysts expect that Repare Therapeutics will post -2.04 EPS for the current fiscal year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.